Dentsply Sirona to Benefit From Dental Market Inflection, CEO Actions, BofA Says

MT Newswires Live02-20

Dentsply Sirona's (XRAY) new Chief Executive Dan Scavilla is acting with urgency to mend channel relationships and the company may also be seeing the start of an inflection point in the dental market, BofA Securities said in a note Thursday.

Dentsply's results next week may "cause volatility" as the company's management may decide to cut the dividend, pledge high investments, and release an outlook below consensus estimates, the note said.

However, BofA said it would see this as a "potential attractive opportunity, as these decisions combined with new management's progress in repairing distributor relationships could support line of sight into growth stabilizing over the medium term."

The note said Dentsply's risk/reward "finally skews positive" even if the company's management cuts its dividend and EPS outlook comes in below consensus estimates.

BofA upgraded Dentsply to buy from neutral and lifted the company's price target to $17 from $13.

Price: 12.72, Change: +0.23, Percent Change: +1.80

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment